We are live on ! Find out more
AMLX icon

Amylyx Pharmaceuticals

171 hedge funds and large institutions have $1.59B invested in Amylyx Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 62 increasing their positions, 53 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

503% more call options, than puts

Call options by funds: $9.02M | Put options by funds: $1.5M

17% more repeat investments, than reductions

Existing positions increased: 62 | Existing positions reduced: 53

17% more capital invested

Capital invested by funds: $1.36B → $1.59B (+$230M)

1.02% more ownership

Funds ownership: 102.24%103.27% (+1%)

4% less funds holding

Funds holding: 179171 (-8)

17% less funds holding in top 10

Funds holding in top 10: 65 (-1)

19% less first-time investments, than exits

New positions opened: 29 | Existing positions closed: 36

Holders
171
Holders Change
-8
Holders Change %
-4.47%
% of All Funds
2.1%
Holding in Top 10
5
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-16.67%
% of All Funds
0.06%
New
29
Increased
62
Reduced
53
Closed
36
Calls
$9.02M
Puts
$1.5M
Net Calls
+$7.52M
Net Calls Change
+$2.34M
Name Holding Trade Value Shares
Change
Change in
Stake
Bank of New York Mellon
51
Bank of New York Mellon
New York
$3.49M +$475K +33,757 +16%
Wellington Management Group
52
Wellington Management Group
Massachusetts
$3.36M +$222K +15,770 +7%
SC
53
SummitTX Capital
Texas
$3.16M +$121K +8,611 +4%
AC
54
Aldebaran Capital
Indiana
$2.75M -$8.66K -616 -0.3%
Invesco
55
Invesco
Georgia
$2.39M -$60.4K -4,294 -2%
Two Sigma Investments
56
Two Sigma Investments
New York
$2.25M -$2.57M -182,456 -53%
UBS AM
57
UBS AM
Illinois
$2.18M +$819K +58,251 +59%
ACP
58
Acuta Capital Partners
California
$2.1M -$2.56M -182,191 -55%
JP Morgan Chase
59
JP Morgan Chase
New York
$2.04M +$1.31M +93,116 +140%
PHS
60
PFM Health Sciences
California
$2.02M +$151K +10,726 +8%
AWG
61
Alpha Wave Global
New York
$1.98M -$2.47M -175,342 -55%
Swiss National Bank
62
Swiss National Bank
Switzerland
$1.81M -$442K -31,400 -19%
T. Rowe Price Associates
63
T. Rowe Price Associates
Maryland
$1.69M +$195K +13,891 +13%
Squarepoint
64
Squarepoint
New York
$1.6M +$539K +38,315 +50%
EC
65
Elmind Capital
New York
$1.56M
RhumbLine Advisers
66
RhumbLine Advisers
Massachusetts
$1.51M +$129K +9,193 +9%
Point72 Asset Management
67
Point72 Asset Management
Connecticut
$1.48M -$3.21M -228,465 -68%
AA
68
ALPS Advisors
Colorado
$1.25M -$2.66K -189 -0.2%
SEI Investments
69
SEI Investments
Pennsylvania
$1.19M +$456K +32,423 +61%
SSA
70
Schonfeld Strategic Advisors
New York
$1.08M +$798K +56,742 +270%
Wells Fargo
71
Wells Fargo
California
$1.04M -$1M -71,226 -49%
D.E. Shaw & Co
72
D.E. Shaw & Co
New York
$1.03M +$14.2K +1,006 +1%
State of Wisconsin Investment Board
73
State of Wisconsin Investment Board
Wisconsin
$1M -$170K -12,083 -14%
AllianceBernstein
74
AllianceBernstein
Tennessee
$976K +$131K +9,300 +13%
California State Teachers Retirement System (CalSTRS)
75
California State Teachers Retirement System (CalSTRS)
California
$904K -$198K -14,088 -18%

AMLX Hedge Fund Activity: Q1 2026 in Review

171 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Amylyx Pharmaceuticals (AMLX) for Q1 2026, worth a combined $1.59B — up 17% from $1.36B a quarter earlier.

Sellers outnumbered buyers: 36 funds closed out of AMLX and 29 opened new positions — a net loss of 7 holders — while 53 trimmed existing stakes and 62 added.

The largest buyer was Siren LLC, opening a new position worth an estimated $17.3M. The largest seller was Sofinnova Investments, exiting entirely with an estimated $6.37M sold.

  • 171 institutional investors held Amylyx Pharmaceuticals (AMLX) as of Q1 2026, down from 179 in Q4 2025.
  • Funds reported $1.59B of Amylyx Pharmaceuticals stock for Q1 2026, up 17% quarter-over-quarter.
  • 29 funds opened new Amylyx Pharmaceuticals positions in Q1 2026 and 36 closed out, a net change of -7 holders.
  • The largest Amylyx Pharmaceuticals buyer in Q1 2026 was Siren LLC, an estimated $17.3M added.
  • The largest Amylyx Pharmaceuticals seller in Q1 2026 was Sofinnova Investments, an estimated $6.37M sold.

Based on aggregated 13F filings for Q1 2026.